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Abstract
 
Dok-1 and Dok-2 are closely related rasGAP-associated docking proteins expressed preferentially
in hematopoietic cells. Although they are phosphorylated upon activation of many protein ty-
rosine kinases (PTKs), including those coupled with cytokine receptors and oncogenic PTKs
like Bcr-Abl, their physiological roles are largely unidentified. Here, we generated mice lacking
Dok-1 and/or Dok-2, which included the double-deficient mice succumbed to myeloproliferative
disease resembling human chronic myelogenous leukemia (CML) and chronic myelomono-
cytic leukemia. The double-deficient mice displayed medullary and extramedullary hyperplasia
of granulocyte/macrophage progenitors with leukemic potential, and their myeloid cells
showed hyperproliferation and hypo-apoptosis upon treatment and deprivation of cytokines,
respectively. Consistently, the mutant myeloid cells showed enhanced Erk and Akt activation
upon cytokine stimulation. Moreover, loss of Dok-1 and/or Dok-2 induced blastic transforma-
tion of chronic phase CML-like disease in mice carrying the 
 
bcr-abl
 
 gene, a cause of CML.
These findings demonstrate that Dok-1 and Dok-2 are key negative regulators of cytokine responses
and are essential for myeloid homeostasis and suppression of leukemia.
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Introduction
 
Dok-1 was first identified as a major substrate of oncogenic
protein tyrosine kinases (1, 2). Among the mammalian Dok
family, Dok-1, Dok-2, and Dok-3 are preferentially ex-
pressed in hematopoietic cells and share structural similari-
ties characterized by NH
 
2
 
-terminal PH and PTB domains,
followed by COOH-terminal SH2 target motifs (3–7).
However, Dok-3 appears relatively distant and does not
bind p120 rasGAP unlike Dok-1 and Dok-2 (6, 7). More
distant Dok family members, Dok-4 and Dok-5, are virtu-
ally absent in hematopoietic cells. A variety of growth
factors and cytokines induce tyrosine phosphorylation of
Dok-1 and Dok-2, providing multiple docking sites for
SH2-containing proteins such as Nck, SHP-1, SHIP-1,
and p120 rasGAP, an inhibitor of Ras (4, 8–10). Experi-
ments with Dok-1-deficient (Dok-1
 
 
 
/
 
 
 
) mice demonstrated
an indispensable role in the negative regulation of Ras and
Erk downstream of protein tyrosine kinases (11–13). Al-
though enhanced Ras signaling often leads to cell prolifera-
tive disease or malignancy (14), Dok-1
 
 
 
/
 
  
 
mice did not dis-
play overt defects in hematopoiesis, suggesting overlap in
functions of Dok-1 and its closest family, Dok-2. Although
ectopic expression of Dok-2 negatively regulates Erk and T
cell development (5, 15), the physiological function of
Dok-2 has yet to be revealed. To understand the role of
Dok-1 and Dok-2 in vivo, we have generated a null muta-
tion in the mouse 
 
dok-2
 
 gene and have crossed Dok-2
 
 
 
/
 
 
 
mice with Dok-1
 
 
 
/
 
  
 
mice.
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Materials and Methods
 
Mice.
 
Dok-2
 
 
 
/
 
  
 
mice were generated by homologous re-
combination (see Fig. S1 and Supplemental Materials and Meth-
ods below) and crossed with Dok-1
 
 
 
/
 
  
 
mice to generate Dok-1/
Dok-2 double-deficient (dKO) animals. Although initial experi-
ments had been performed with the mixed background mice of
129/SvJ and C57BL/6, mice were crossed over eight times to the
C57BL/6 background for detailed experiments (see Figs. 2, D–I,
and 3). The 
 
bcr-abl
 
 transgenic line was generated elsewhere (16).
Mice were maintained under specific pathogen-free conditions.
Experiments and animal care were performed according to insti-
tutional guidelines.
 
Histology and Immunohistochemistry.
 
Tissue sections were
stained with hematoxylin and eosin. Cytospin preparations and
blood smears were stained with Wright and Giemsa solutions
(Sigma-Aldrich). For immunohistochemistry, tissue sections were
stained with antibodies to Mac-1 (BD Biosciences) or to F4/80 (Se-
rotec). Isotype-matched immunoglobulins were used as controls.
 
Flow Cytometry.
 
Mononuclear cells were stained with the fol-
lowing FITC-, PE-, or biotin-conjugated primary antibodies: anti–
Gr-1, Mac-1, CD4, CD8, CD45.1/Ly5.1, and CD45.2/Ly5.2
(BD Biosciences). Streptavidin–quantum red conjugate (Sigma-
Aldrich) was used for biotin-coupled antibody. Antibody-stained
cells were analyzed with FACSCalibur (BD Biosciences).
 
Colony Formation Assay.
 
2–2.5 
 
  
 
10
 
4 
 
bone marrow cells or
10
 
5 
 
spleen cells were plated in 1.2% 
 
 
 
MEM-based methylcellu-
lose medium containing 30% FCS and 1% BSA in the absence or
presence of a combination of 100 ng/ml mSCF (PeproTech), 10
ng/ml mIL-3, 10 ng/ml hG-CSF, 2 U/ml hEpo (Kirin Brew-
ery), 100 ng/ml hIL-6 (Tosoh), and 100 U/ml mIL-7 (Toray) in
35-mm plates. The number of colonies over 50 cells was scored
as described previously (17).
 
Bone Marrow–derived Mast Cells (BMMCs) and Bone Marrow–
derived Macrophages (BMM
 
 
 
s).
 
Bone marrow cells from 8-wk-old
mice were cultured in RPMI 1640 medium containing 10% FCS
and 10 ng/ml mIL-3 (PeproTech) for the first 2 wk, and then 10
ng/ml mSCF was added. More than 95% of the nonadherent
cells were confirmed as Fc
 
 
 
RI
 
  
 
c-Kit
 
  
 
Sca-1
 
  
 
after 4 wk of cul-
ture, and the BMMCs were used up to an additional 4 wk. Bone
marrow cells from 8-wk-old mice were cultured in RPMI 1640
medium containing 10% FCS and 10 ng/ml mM-CSF (Pepro-
Tech) for 7 d to establish adherent BMM
 
 
 
s.
 
Proliferation and Apoptosis Assays.
 
For proliferation assay, BM-
MCs were seeded at 10
 
5 
 
cells/well in 96-well plates, cultured for
48 h in RPMI 1640 medium containing 10% FCS and mSCF or
mIL-3 (PeproTech), and then pulse labeled for 8 h with 0.2 
 
 
 
Ci
[
 
3
 
H]thymidine/well. BMM
 
 
 
s were plated at 10
 
4 
 
cells/well in 96-
well plates, cultured in RPMI 1640 medium containing 10%
FCS and mM-CSF or mGM-CSF (PeproTech), and then viable
cells were stained with MTT (Sigma-Aldrich). Bone marrow
cells were seeded at 5 
 
  
 
10
 
4 
 
cells/well in 96-well plates, cultured
in RPMI 1640 medium containing 10% FCS in the presence or
absence of mSCF or hG-CSF, and then stained with MTT. For
apoptosis assay, BMMCs were seeded at 10
 
6 
 
cells/well in 24-well
plates, cultured in RPMI 1640 medium containing 10% FCS,
mSCF, and mIL-3, and then subjected to flow cytometry with an
annexin V-FITC apoptosis detection kit (BD Biosciences).
 
Immunoblotting.
 
BMM
 
 
 
s were solubilized in the SDS-load-
ing buffer. Proteins in cell lysates were separated by SDS-PAGE,
transferred to PVDF membrane, and visualized with the follow-
ing antibodies: anti-Erk1/Erk2 (Santa Cruz Biotechnology, Inc.),
phospho-Erk (p-Erk; New England Biolabs, Inc.), and phospho-
Akt (p-Akt) or Akt (Cell Signaling).
 
Transplantation.
 
2 
 
  
 
10
 
6 
 
bone marrow cells from the donor
were injected into the tail vein of lethally irradiated (9.5 Gy) re-
cipients at 2–4 mo of age. The donor and recipient cells were dis-
tinguished by the expression of Ly5.1 and Ly5.2.
 
Online Supplemental Material.
 
Fig. S1 shows a generation of
 
dok-2
 
–null mice and 
 
dok-1
 
 and 
 
dok-2
 
 expression in hematopoietic
cells. Table S1 shows accumulation of immature myeloid cells and
neutrophils/monocytes in dKO spleen and peripheral blood, re-
spectively. Fig. S2 and Table S2 show down-regulation of Dok-1
and Dok-2 in human leukemia cell lines. Tables S3 and S4 show
the pathological examination of 
 
bcr-abl
 
 transgenic mice lacking
Dok-1 and/or Dok-2. Fig. S3 shows clonal evolution of imma-
ture T cell blasts developed in Bcr-Abl mice lacking Dok-1 and/
or Dok-2. Methods regarding these experiments are described in
Supplemental Materials and Methods. Figs. S1–S3, Tables S1–S4,
and Supplemental Materials and Methods are available at http://
www.jem.org/cgi/content/full/jem.20041247/DC1.
 
Results and Discussion
 
Dok-1/Dok-2 Double-deficient Mice Succumbed to Myelopro-
liferative Disease.
 
Dok-2
 
 
 
/
 
  
 
mice were generated by ho-
mologous recombination and crossed with Dok-1
 
 
 
/
 
  
 
mice
to generate Dok-1/Dok-2 double-deficient (dKO) ani-
mals (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20041247/DC1). These mice were via-
ble, fertile, and born at the Mendelian frequency. 7 of 13
dKO mice, but not the others, developed myeloprolifera-
tive disease at 
 
 
 
1 yr of age, accompanied by an enlarge-
ment of the spleen where immature and mature granulo-
cytes/monocytes, erythroblasts, and atypical myeloid cells
were accumulated (Fig. 1, A and B, and Table S1, available
at http://www.jem.org/cgi/content/full/jem.20041247/
DC1). These atypical cells resemble the myelomonocytic
cells in Gfi-1–deficient mice (18). dKO bone marrow or
spleen cells showed an increased ratio of immature granu-
locytic and/or monocytic precursors (Gr-1
 
 
 
/low
 
 
 
Mac-1
 
 
 
;
Fig. 1 C). Pathological studies of dKO mice also revealed
extramedullary hematopoiesis in the spleen, hyperplasia of
megakaryocytes and myeloid progenitors at various stages
in the bone marrow, and pronounced cellular infiltrations
of granulocytes and lymphocytes in several organs (Fig. 1
D and not depicted). The leukocyte number in the dKO
peripheral blood was much higher than that of the other
mice (Fig. 1 E), and the dKO leukocytes showed enlarged
neutrophil (Gr-1
 
high 
 
Mac-1
 
 
 
) and monocyte (Gr-1
 
 
 
/low
 
Mac-1
 
 
 
) populations (Fig. 1, C and E, and Table S1). In-
terestingly, half of the dKO mice with myeloproliferative
disease developed histiocytic sarcoma of macrophage ori-
gin (Fig. 1 F). These results indicate that the dKO mice
developed myeloproliferative disease resembling human
chronic myelogenous leukemia (CML) and chronic my-
elomonocytic leukemia (CMMoL) as well as macrophage
tumor. However, it is of note that these dKO mice re-
quired several months of latency to develop CML-like dis-
ease and that 6 of 13 dKO mice did not succumb to it un-
til 
 
 
 
1 yr of age, suggesting an involvement of additional
genetic changes. 
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As dKO mice developed hyperplasia of myeloid precur-
sors, we evaluated the clonogenic potential of the com-
mon myeloid progenitor (CFU-GEMM), granulocyte/mac-
rophage lineage-restricted progenitor (CFU-GM), or B cell
progenitor (CFU-preB). Numbers of CFU-preB in the
bone marrow were not significantly different among the
mice tested at 4 mo of age, and the number of CFU-
GEMM in the bone marrow was slightly increased in dKO
mice (Fig. 2, A and B). The number of CFU-GM in the
bone marrow of Dok-1
 
 
 
/
 
 
 
, Dok-2
 
 
 
/
 
 
 
, and dKO mice was
increased as compared with the number in wild-type mice.
However, the number of CFU-GM in the spleen of dKO
mice was dramatically increased, whereas the number of
CFU-GEMM in the spleen varied only slightly (Fig. 2 C).
These results indicate that the neutrophilic and monocytic
hyperplasia observed in dKO mice, at least in part, is due to
hyperplasia of CFU-GM in the bone marrow and subse-
quent extramedullary myelopoiesis in the spleen. Given
that dKO mice showed hyperplasia of erythroblasts and
megakaryocytes, Dok-1 and Dok-2 may also have an in-
hibitory function in the generation of their precursor cells.
 
Myeloid Cells Lacking Dok-1 and Dok-2 Are Hyperrespon-
sive to Cytokines.
 
To elucidate how the myeloproliferative
disease developed in dKO mice, we examined growth or
survival responses of BMMCs or BMM
 
 
 
s from wild-type,
Dok-1
 
 
 
/
 
 
 
, Dok-2
 
 
 
/
 
 
 
, or dKO mice at 8 wk of age upon
stimulation with cytokines involved in myelopoiesis. Note
that these mutant mice appeared normal in hematopoiesis
at this age. All mutant BMMCs showed a greater prolifera-
tive response than the wild-type cells upon SCF stimula-
tion, whereas only dKO BMMCs were hyperproliferative
to the lower dose of IL-3 (Fig. 2 D). Moreover, all mutant
BMMCs displayed attenuated apoptosis induced by a re-
duction or deprivation of SCF and IL-3 (Fig. 2 E). In any
case, dKO BMMCs showed the best proliferative or anti-
apoptotic response to the cytokines. Although Dok-1
 
 
 
/
 
  
 
or
Dok-2
 
 
 
/
 
  
 
BMM
 
 
 
s displayed a significant increase of pro-
liferation upon M-CSF treatment or the lower dose of
Figure 1. dKO mice develop a
myeloproliferative disease resembling
human CML and CMMoL. (A) Mas-
sive  enlargement of the spleen in
dKO mice compared with wild-type
controls at 13 mo of age (top).
Spleen weights of wild-type (n   25),
Dok-1 /  (n   10), Dok-2 /  (n  
17), and dKO (n   12) mice mea-
sured at 13–15 mo of age (bottom).
The mean value with the SE is dem-
onstrated. (B) Cytospin specimens of
splenocytes from dKO mice at 15
mo of age are characteristic of my-
eloproliferative disease with marked
myeloid hyperplasia comprised of
granulocytes/monocytes in various
stages of differentiation, including
atypical myeloid cells (arrowheads).
(C) Flow cytometry for Mac-1 and
Gr-1 on bone marrow, spleen, or
peripheral blood cells from mice at
15 mo of age. (D) Mononuclear cell
infiltration into perivascular areas in
dKO kidney and liver. Higher mag-
nification of each boxed area (bottom)
shows the infiltrating neutrophils
(arrowheads). (E) Leukocytes (left)
or erythrocytes (middle) in periph-
eral blood of wild-type (n     22),
Dok-1 /  (n   6), Dok-2 /  (n   7),
or dKO (n   12) mice at 13–15 mo
of age were enumerated, and mean
values with each SE are demon-
strated. Differential cell counts were
determined (right) from peripheral
blood smears of wild-type ( ) or
dKO ( ) mice and are demonstrated
with each mean value. Ne, neutro-
phil; Mo, monocyte; Eo, eosinophil;
Ly, lymphocyte. (F) Gross appear-
ance of enlarged dKO kidneys bear-
ing histiocytic sarcoma or wild-type
controls for each mouse at 15 mo of age (left). Histological sections of dKO kidney were stained for macrophage markers Mac-1 or F4/80 (right). Posi-
tively stained tumor cells surround unstained cells in the glomerulus (G) and uriniferous tubules (U). Statistical significance compared with wild-type was
determined with the Student’s t test. *, P   0.01.Role of Dok-1 and Dok-2 in Myelopoiesis 1684
GM-CSF treatment, dKO BMM s always showed the
greatest response, especially to the higher dose of each cy-
tokine (Fig. 2 F). Finally, we examined the growth re-
sponse upon G-CSF stimulation of primary bone marrow
cells, as neither BMMCs nor BMM s react to this cyto-
kine, and found that bone marrow cells lacking Dok-1 and/
or Dok-2 show normal growth to G-CSF, but elevated
growth to SCF (Fig. 2 G). Together, our findings indicate
that Dok-1 and Dok-2 work cooperatively in the negative
regulation of these cytokine signaling except G-CSF. As
we confirmed their expression in premature and mature
myeloid cells (Fig. S1), this cooperative function likely ex-
plains why dKO mice, but not Dok-1 /  or Dok-2 / 
mice, displayed aberrant myelopoiesis, macrophage tumors,
and myeloid leukemia. However, of note is that these cy-
tokines can induce CFU-GEMM as well as CFU-GM in
vitro, suggesting that Dok-1 and Dok-2 have limited in-
hibitory functions in CFU-GEMM and/or that these cy-
tokines have limited effects to it in vivo.
M-CSF stimulation of monocytic cells triggers Ras/Erk
and PI-3K/Akt pathways facilitating cellular proliferation
and survival, and it also induces tyrosine phosphorylation of
Figure 2. Hyperplasia of granu-
locyte/macrophage progenitors in
dKO mice and hyperactivation of
their myeloid cells upon stimula-
tion with cytokines. (A–C) Col-
ony formation assays for CFU-
GEMM (GEMM), CFU-GM
(GM), or CFU-preB (preB) were
performed with bone marrow or
spleen cells of the mice at 4 mo
of age in the presence of the indi-
cated cytokine(s). Statistical signifi-
cance compared with wild-type
was determined with the Student’s
t test. *, P   0.01; **, P   0.001.
(D and E) Proliferation and apop-
tosis of BMMCs were evaluated
based on [3H]thymidine incorpo-
ration and annexin V binding, re-
spectively, in the presence or ab-
sence of the indicated cytokine(s).
Apoptotic rates were determined
after the indicated culture period.
(F) The proliferation of BMM s
was evaluated with the MTT assay
after 5 d of culture in the presence
of the indicated cytokine. (G) The
proliferation of bone marrow
cells from mice at 8 wk of age
was evaluated with the MTT assay
after 4 d of culture in the absence
or presence (10 ng/ml) of the in-
dicated cytokine. (A–G) Mean
values and SEs are from triplicate
experiments. (H) Activated Erk
(p-Erk1/2), Akt (p-Akt), total
Erk1/2, or Akt was examined
with immunoblotting upon
M-CSF treatment (10 ng/ml) of
BMM s. The position of each
protein and period of stimulation
are indicated. (I) Colony forma-
tion assay was performed with
bone marrow cells of mice at 8
wk of age in the absence of cy-
tokine. Mean values and SEs are
from triplicate experiments.Yasuda et al. Brief Definitive Report 1685
Dok-1 and Dok-2 (8, 9). Thus, we evaluated M-CSF–
induced Erk and Akt activation in Dok-1 / , Dok-2 / , or
dKO BMM s (Fig. 2 H). Although cells lacking Dok-1 or
Dok-2 showed enhanced activation of both Erk and Akt, a
more vigorous activation was obvious in the dKO mac-
rophages, indicating that Dok-1 and Dok-2 cooperatively
suppress Erk and Akt upon cytokine stimulation. Further,
the dKO macrophages showed cytokine-independent acti-
vation of Erk. Therefore, we addressed the cytokine-inde-
pendent clonogenicity of bone marrow cells from 8-wk-old
mice and found that dKO bone marrow cells formed  20
colonies of  100 cells and Dok-1 /  or Dok-2 /  cells
formed a few colonies of  100 cells, whereas wild-type
cells formed no colony (Fig. 2 I). These results indicate that
Figure 3. Cell autonomous progression of myelo-
proliferative disease in the absence of Dok-1 and Dok-2.
Hematopoietic cells in lethally irradiated wild-type
(Ly5.1 or Ly5.2 allotype) or dKO mice (Ly5.2) were
reconstituted with bone marrow cells from 8-wk-old
wild-type (Ly5.1 or Ly5.2) or dKO (Ly5.2) mice. Flow
cytometry on peripheral blood cells of each recipient
was performed at 9 mo after transplantation. The donor-
derived myeloid cell compartment is circled in forward
scatter (FSC) versus side scatter (SSC) parameters (top).
Gr-1 and Mac-1 expression on donor-derived cells in pe-
ripheral blood of each recipient was also examined (bot-
tom). Mice are with the C57BL/6 genetic background.
Figure 4. Dok-1 and Dok-2 suppress the blastic
transformation of the Bcr-Abl–induced CML-like disease.
(A) Survival curves for Bcr-Abl mice lacking Dok-1
and/or Dok-2 and the nontransgenic controls. HH,
HK, KH, and KK stand for mice with the dok-1 / :
dok-2 / , dok-1 / : dok-2 / , dok-1 / : dok-2 / , and
dok-1 / : dok-2 /  loci, respectively, and T stands for
mice carrying the bcr-abl transgene. For each genotype,
10 mice were monitored. Log rank statistical analysis
was performed (*, P   0.03, compared with the THH
mice). (B) Tumors that developed in the lymph nodes
(left, arrowheads) and thymus (right, arrow) of a TKK
mouse (No. 4). (C) Lymphoblasts in tumors developed
in lymph nodes of mice. (D) Surface expression of
CD4 and CD8 on mononuclear cells in lymph nodes
(LN), thymus (Thy), or peripheral blood (PB) of mice at 4
mo of age examined with flow cytometry. The HH mice
were analyzed as an age-matched control. (E) Lympho-
blasts in gastrointestinal lymphomas developed in large
intestines of mice at 7 mo of age. The HH mouse was
analyzed as an age-matched control.Role of Dok-1 and Dok-2 in Myelopoiesis 1686
dKO progenitors gained enhanced growth capability result-
ing in their cytokine-independent hyper-clonogenicity.
Myeloproliferative Disease in dKO Mice Is Cell Autonomous.
To test whether myeloproliferative disease in dKO mice is
cell autonomous, bone marrow cells from 8-wk-old Ly5.2 
dKO mice were transferred into irradiated Ly5.1  wild-type
mice. 9 mo after the transplantation, 7 of 10 recipients re-
constituted with dKO cells showed hyperplasia of circulat-
ing neutrophils (Gr-1high Mac-1 ; Fig. 3); however, none of
the recipients reconstituted with Ly5.2  or Ly5.1  wild-
type cells showed such abnormality, regardless of the dok-1
and dok-2 mutations. Although the transmitted abnormality
is weaker than that seen in dKO mice with mixed genetic
background (Fig. 1 C), it is probably because the transplan-
tation was performed with C57BL/6 background, which is
relatively resistant to bcr-abl–induced leukemogenesis (19).
Together, these results indicate that the myeloproliferative
disease in dKO mice is cell autonomous.
Dok-1 and Dok-2 Suppress Blastic Transformation of CML-
like Disease. Human CML is caused by Bcr-Abl, which
phosphorylates Dok-1 and Dok-2 in hematopoietic stem/
progenitor cells of patients with CML (1, 3). As the disease
progresses, lethal blastic transformation into acute leukemia
or lymphoma, termed blast crisis, occurs. Recently, the dok-2
gene was identified as 1 of the 21 most down-regulated
genes in the bone marrow cells of patients with CML at blast
crisis among 5,315 genes analyzed (20). In addition, we
found that four of eight leukemia cell lines established from
such patients express undetectable or marginal levels of Dok-1
and/or Dok-2, suggesting their negative roles in the blastic
transformation (Fig. S2 and Table S2). However, it was diffi-
cult to examine the role of these adaptors in the blastic trans-
formation because Bcr-Abl–induced CML-like disease in
mice usually displayed no chronic phase (12, 19). Exception-
ally, a tec promoter-p210bcr-abl transgenic line (Bcr-Abl mice,
hereafter) routinely developed chronic phase CML-like dis-
ease at  6–8 mo after birth, and the chronic phase lasted at
least until 1 yr of age (16). Therefore, we prepared Bcr-Abl
mice lacking Dok-1 and/or Dok-2 to elucidate the roles of
Dok-1 and Dok-2 in the clinical progression of CML (Table
S3). 5 of the 30 Bcr-Abl mice lacking Dok-1 (TKH), Dok-2
(THK), or both (TKK) died at 4–5 mo after birth, and most
of the others died at 6–9 mo after birth, whereas very few of
the controls died (Fig. 4 A). Although loss of either adaptor
induced early lethality of Bcr-Abl mice, this could be due to
haploinsufficiency of each gene to replace the other’s func-
tion because these Bcr-Abl mice lacking Dok-1 or Dok-2
had only one allele of wild-type dok-2 or dok-1 gene, respec-
tively. Alternatively, Dok-1 and Dok-2 functions may not
be mutually replaceable in this respect. Pathological exami-
nation of dead or moribund mice revealed that some of the
THK, TKH, and TKK mice developed a severe enlarge-
ment of the thymus and lymph nodes with a massive infiltra-
tion of lymphoblasts at 4–5 mo of age (Fig. 4, B and C,
and Table S4). The infiltrated tumor cells were composed
of CD4/CD8 double-positive immature T lymphoblasts,
which also comprised a large part of the peripheral blood
cells, indicating severe blastic transformation (Fig. 4 D and
Table S4). Southern blot analysis further revealed that these
tumors carried rearrangements in the T cell receptor   locus,
indicating that the blast cells were clonal in origin (Fig. S3).
At 7–8 mo of age, many of the THK, TKH, and TKK mice,
but not the controls, were moribund or dead. They showed
a massive infiltration of lymphoblastoid cells in the gas-
trointestinal tracts in addition to aggravated CML-like symp-
toms (Fig. 4 E and Table S4). The infiltrates showed a mo-
notonous morphology and the pattern was diffuse in many
parts, accompanied with several foci of lymphoepithelial le-
sions, indicating blastic transformation into gastrointestinal
lymphoma. Together, these results demonstrate that Dok-1
and Dok-2 are essential to suppress the blastic transformation
of the Bcr-Abl–induced CML-like disease. However, it is of
note that in case of patients with CML, blast crisis mostly re-
sults in myeloid or B cell leukemia/lymphoma, usually not
in the T cell variety. That Bcr-Abl mice carrying a p53 mu-
tation also developed T cell lymphoma suggests involvement
of genetic background (21).
Here, we reported that Dok-1 and Dok-2 inhibit cyto-
kine-mediated proliferative and antiapoptotic signaling in
myeloid cells and oppose myeloid leukemogenesis and
blastic transformation of CML-like disease in mice. That
loss of Dok-1 and/or Dok-2 induced the blastic transfor-
mation of Bcr-Abl–induced CML-like disease into lym-
phoma suggests their roles in hematopoietic stem cells,
where the tec gene promoter, which controls the bcr-abl
transgene, is preferentially active (16). Moreover, as dKO
mice developed myeloproliferative disease in the absence of
Bcr-Abl, Dok-1 and Dok-2 may oppose a wide range of
myeloid leukemogenesis in humans. Consistently, unde-
tectable or marginal levels of their expression was observed
in about half of the leukemic cell lines established from pa-
tients with myeloid leukemia, regardless of whether it is
CML or not (Fig. S2 and Table S2). Further investigation
of the tumor suppressive function of Dok-1 and Dok-2 in
human malignancies, especially myeloid leukemias includ-
ing CML and CMMoL, might lead to an understanding of
the molecular mechanisms of such diseases and contribute
to designing effective therapies against them.
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